In a previous white paper, we explored the challenges pharmaceutical companies face in selecting the right European distribution partners and in building sustainable, mutually beneficial partnerships. Now, we shift our focus to the complexity of the European pharmaceutical distribution network, asking a key question: Can a centralized distribution model work in Europe, or do the continent’s market realities, regulations, infrastructure, and specific therapy requirements demand a more tailored approach?

This paper examines the market dynamics and role of third-party logistics (3PL) in Europe, examines six critical centralization considerations, and explores why a hybrid distribution model may offer the optimal balance for pharmaceutical companies operating across Europe.